NEO - NeoGenomics Inc Stock Price, Fair Value and News

$15.79+0.40 (+2.60%)

Delayed as of 22 Nov 2024, 11:00 am ET

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

NEO Price Action

Last 7 days

-2.5%

Last 30 days

16.4%

Last 90 days

-7.6%

Trailing 12 Months

-19.4%

NEO RSI Chart

NEO Valuation

Market Cap

2.0B

Price/Earnings (Trailing)

-25.42

Price/Sales (Trailing)

3.07

EV/EBITDA

-72.38

Price/Free Cashflow

-91.83

NEO Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

NEO Fundamentals

NEO Revenue

Revenue (TTM)

644.1M

Rev. Growth (Yr)

10.44%

Rev. Growth (Qtr)

2.02%

NEO Earnings

Earnings (TTM)

-77.7M

Earnings Growth (Yr)

4.41%

Earnings Growth (Qtr)

5.06%

NEO Profitability

EBT Margin

-12.39%

Return on Equity

-8.56%

Return on Assets

-4.74%

Free Cashflow Yield

-1.09%

NEO Investor Care

Shares Dilution (1Y)

0.70%

NEO Alerts

JANUS HENDERSON GROUP PLC reported owning 5.2% of NEO [2024-11-14]
Losses in recent quarter

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	610.7M	628.2M	644.1M	0
2023	529.8M	551.6M	574.8M	591.6M
2022	486.0M	489.3M	496.8M	509.7M
2021	454.0M	488.7M	484.6M	484.3M
2020	419.3M	404.5M	425.3M	444.4M
2019	308.9M	342.9M	378.4M	408.8M
2018	246.2M	251.7M	261.7M	276.7M
2017	241.8M	240.9M	239.3M	240.3M
2016	136.5M	175.2M	210.9M	244.1M
2015	91.9M	95.6M	97.5M	99.8M
2014	69.0M	74.1M	80.4M	87.1M
2013	60.4M	60.4M	63.0M	66.5M
2012	49.8M	55.0M	57.9M	59.9M
2011	36.6M	38.9M	41.2M	43.5M
2010	0	0	0	34.4M

Get all data in R, Python etc through our Historical Stock Data APIs

About NeoGenomics Inc

NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. It operates through, Clinical Services and Pharma Services segments. The company offers testing services to hospitals, reference labs, pathologists, oncologists, clinicians, pharmaceutical firms, and researchers. It provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. The company also provides molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization, as well as acts as a reference laboratory supplying anatomic pathology testing services. It has a strategic alliance agreement and laboratory services agreement with Inivata Limited. The company was founded in 2001 and is headquartered in Fort Myers, Florida.

CEO	Mr. Christopher Michael Smith BSc
WEBSITE	neogenomics.com
SECTOR	Healthcare
INDUSTRY	Diagnostics & Research
EMPLOYEES	2100

NeoGenomics Inc Frequently Asked Questions

What is the ticker symbol for NeoGenomics Inc? What does NEO stand for in stocks?

NEO is the stock ticker symbol of NeoGenomics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of NeoGenomics Inc (NEO)?

As of Thu Nov 21 2024, market cap of NeoGenomics Inc is 1.98 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of NEO stock?

You can check NEO's fair value in chart for subscribers.

Is NeoGenomics Inc a good stock to buy?

The fair value guage provides a quick view whether NEO is over valued or under valued. Whether NeoGenomics Inc is cheap or expensive depends on the assumptions which impact NeoGenomics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for NEO.

What is NeoGenomics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Nov 21 2024, NEO's PE ratio (Price to Earnings) is -25.42 and Price to Sales (PS) ratio is 3.07. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. NEO PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on NeoGenomics Inc's stock?

In the past 10 years, NeoGenomics Inc has provided 0.133 (multiply by 100 for percentage) rate of return.